Buscar
Plus Therapeutics Inc
PSTVAñadir a la lista de seguimiento
3.870USD
+0.220+6.03%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.06MCap. mercado
PérdidaP/E TTM
Más Datos de Plus Therapeutics Inc Compañía
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. Combining image-guided local beta radiation and targeted drug delivery approaches, it is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers including primary and secondary liver cancers via intra-arterial injections.
Información de Plus Therapeutics Inc
Símbolo de cotizaciónPSTV
Nombre de la empresaPlus Therapeutics Inc
Fecha de salida a bolsaAug 09, 2000
Director ejecutivoHedrick (Marc H)
Número de empleados21
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 09
Dirección4200 Marathon Blvd.
CiudadAUSTIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal78756
Teléfono17372557194
Sitio Webhttp://www.plustherapeutics.com/
Símbolo de cotizaciónPSTV
Fecha de salida a bolsaAug 09, 2000
Director ejecutivoHedrick (Marc H)
Ejecutivos de Plus Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
44.48K
+36.96%
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
5.57K
--
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
1.98K
+46.52%
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
44.48K
+36.96%
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
5.57K
--
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
1.98K
+46.52%
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Plus Therapeutics Inc?
Los cinco principales accionistas de Plus Therapeutics Inc son: Dr. Marc H. Hedrick, M.D.
¿Cuántas instituciones poseen acciones de Plus Therapeutics Inc (PSTV)?
A fecha de 2026Q1, 55 instituciones poseen acciones de Plus Therapeutics Inc, con un valor de mercado combinado de aproximadamente 1.08M, lo que representa el 15.74% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 825853.00.
¿Cuál es la mayor fuente de ganancias de Plus Therapeutics Inc?
El 2026Q1, el segmento empresarial Consumable generó la ganancia más alta para Plus Therapeutics Inc, ascendiendo a 2.17M y representando el 81.21% de la ganancia total.